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A 68-year-oldCaucasian femalewas admitted to the emergency departmentwith a progressive history of behavioural symptoms and
anxiety followed by visual and auditory hallucinations, forgetfulness, and impaired gait in the previous 3 months. On examination
she was psychotic and had a postural and rest tremor of the upper limbs, cogwheel rigidity of the four limbs, retropulsion on
standing position, and inability to walk. During the following 2 weeks she developed xerostomia and unilateral parotiditis that
improved with steroids. A simultaneous improvement of the cognitive abilities allowed for the detection of sensory ataxia of the
lower limbs. Sensory ganglionopathy was then detected with electrophysiological studies. A diagnosis of Sjo¨gren syndrome was
suspected and confirmed by salivary gland scintigraphy, Schirmer’s test, and submaxillary gland biopsy.We report a case of Sjo¨gren
syndrome associated with central and peripheral nervous system involvement, without sicca symptoms preceding the neurological
clinical picture. The coexistence of ganglionopathy and a favourable response to immunosuppression are key features that can lead
to the correct diagnosis in cases with atypical CNS symptoms, mimicking a rapidly progressive dementia.
1. Introduction
Sjo¨gren syndrome is a common autoimmune disease that can
be either primary or secondary to other autoimmune dis-
eases. Its diagnosis is often difficult because of the wide clini-
cal heterogeneity. Its histopathologic hallmark is the periduc-
tal lymphocytic infiltrate with destruction of salivary and
lacrimal glands resulting in loss of their function, which leads
to sicca symptoms. Parallel mononuclear infiltrate or vas-
culitic lesions may affect other organs and systems. Nervous
system is one of the most common extraglandular involved
sites, and it is reported to precede the sicca symptoms in a
proportion of patients [1]. Neurological manifestations can
involve both peripheral and central nervous systems. In this
case the authors present a case of Sjo¨gren syndrome which
manifested as rapidly progressive dementia with impaired
gait, in the absence of previous sicca symptoms.
2. Case Report
A 68-year-old Caucasian woman was taken by her son to the
emergency department with a 3-month progressive history
of anxiety followed by complex visual and auditory halluci-
nations, forgetfulness, and impaired gait in the previous 2
weeks. She had a history of Hashimoto thyroiditis for over
10 years and was on thyroid hormone replacement therapy
with levothyroxine, without other relevant personal or family
history. General physical examination was unremarkable. On
admission she was alert, agitated, with frightened appearance
and looking around with suspiciousness. She showed space
and time disorientation, impaired attention, and incoherent
speech, verbalizing nonsystematized delusional thoughts of
persecutory type. Cranial nerve examinationwas normal. She
had a postural and rest upper limbs tremor, cogwheel rigidity
of the four limbs, brisk deep tendon reflexes, and a tendency
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Figure 1: Head CT demonstrating left parotiditis.
to fall backwards on standing position and was unable to
walk.
Diagnostic workup was performed with an initial clinical
hypothesis of a rapidly progressive dementia. CSF exami-
nation revealed no cells and an increased protein content
(74mg/dL of the IgG type) with absent oligoclonal bands
and with normal serum immunoglobulin concentration. Test
for 14-3-3 protein was negative. EEG detected a generalized
slowing of background activity, without epileptiform activity.
Brain MRI showed only mild diffuse cortical atrophy.
On day 7 after admission, the patient developed xeros-
tomia and unilateral left parotiditis (Figure 1) that remitted
under oral prednisolone 40mgonce a day.This treatment also
made a marked improvement in cognitive and psychiatric
symptoms over the following days. Neurological reassess-
ment on the 14th day showed weak deep tendon reflexes and
decreased vibration and position senses on lower limbs, with
sensory ataxia, Romberg sign, and wide-based gait. Nerve
conduction studies revealed absent sensory nerve action
potentials of sural nerve bilaterally, with slight decrease of the
amplitude of the compound motor action potentials in the
common peroneal and tibial nerves. Needle EMG was unre-
markable. Somatosensory evoked potentials were compatible
with a dysfunction of the posterior cord below cervical level.
The clinical setting and electrophysiological studies were
compatible with the diagnosis of a sensory ganglionopathy.
With this clinical scenario and steroid responsiveness,
an immune-mediated disease was suspected. The complaints
of xerostomia along with the parotiditis were suggestive of
Sjo¨gren syndrome. Anti-Ro (SSA) and anti-La (SSB) antibod-
ies were repeatedly negative, as were rheumatoid factor and
antinuclear antibodies (ANA). A salivary gland scintigraphy
(99TcO4-) was performed and it revealed severely decreased
uptake in submaxillary and parotid glands (Figure 2). Schir-
mer’s test showed severe reduction of tear production (2mm
bilaterally after 5 minutes) and submaxillary gland biopsy
(Figure 3) identified a multifocal inflammatory lymphocytic
infiltrate with >1 focus/4mm2 (1 focus = 50 lymphocytes),
thus favouring the diagnosis of Sjo¨gren syndrome.
Figure 2: Salivary gland scintigraphy showing decreased uptake in
submaxillary and parotid.
Steroid therapy resulted in global improvement of psychi-
atric and cognitive symptoms, as well as of extrapyramidal
features and sensory ataxia allowing for unassisted gait. Two
months after admission there was a relapse of psychotic
symptoms (delusions—the patient strongly believed that her
sonwas in great danger; visual and tactile hallucinations—she
saw bizarre animals and felt them touching her legs) that were
refractory to oral steroids and antipsychotic drugs, which
led to treatment escalation with cyclophosphamide. After 2
cycles of cyclophosphamide completed, recurrent urinary
tract infections forced its withdrawal, with subsequent wors-
ening of central and peripheral neurologic symptoms. Rit-
uximab treatment was then initiated, in a regimen of two
1000mg IV repeated twice with six months apart. Follow-
ing this treatment, a progressive clinical improvement was
observed.
One year after admittance, neurological reassessment
showed that the patient was oriented in time and space,
with attention and short- and long-term memory preserved.
Cranial nerve examination was unremarkable. The superior
limbs showed a dystonic posture of the wrist with athetosis of
the fingers that were enhanced with the eyes closed.
Normal Strength and Muscle Tone. Absent deep tendon ref-
lexes, decreased vibration, and position senses on the four
limbs, with sensory ataxia and Romberg sign, were observed.
Gait was wide-based but possible with little assistance. The
patient had no psychiatric symptoms and was independent
in all basic daily life activities (Figure 4).
3. Discussion
In primary Sjo¨gren syndrome, neurological manifestations
can be protean and involve both peripheral and central nerv-
ous systems, as exemplified by our patient, whose clinical pic-
ture included cognitive impairment, hallucinations, extrapy-
ramidal features, and sensory ataxia. To the best of our
knowledge, such severe, simultaneous, and rapidly progres-
sive symptoms have not been previously reported.
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Figure 3: Submaxillary gland biopsy. (a) H&E 10 × 20—one focus of lymphocytic infiltrate (black arrow). (b) Immunohistochemistry—T
lymphocytes (CD3+). (c) Immunohistochemistry—B lymphocytes (CD20+).
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Figure 4: Diagram representing the timeline of the relevant clinical events. The time on the arrow refers to the date of emergency room
admittance.
The exact pathophysiology of CNS clinical features
remains unclear. It is thought to be related to an inflammatory
process, affecting small vessels, without causing visible struc-
tural damage [2]. Some authors suggest other mechanisms
such as direct infiltration of theCNS bymononuclear cells [1].
The term Nonvasculitic Autoimmune Meningoencephalitis
was proposed by Caselli et al. in 1999 when describing 5
patients presenting with progressive cognitive decline, with
both serologic evidence of autoimmunity and of tissue infla-
mmation, benefiting from immunosuppression. Interest-
ingly, two out of the five patients from this original report later
received the diagnosis of Sjo¨gren syndrome [3].
There is no clear topographical relationship between the
clinical features and the imaging studies; hence brain MRI is
not useful for diagnosis, showing abnormalities in only 30%
of cases [4]. In this particular case no functional imaging was
performed, so no clinical-anatomical correlation was done.
Regarding the peripheral nervous system involvement,
there is no certainty about the mechanism either. Sensory
ganglionopathy appears to be mediated by direct mononu-
clear infiltration and destruction of the dorsal root ganglion
and the posterior columns of the spinal cord, promoted by the
leaky basement membrane of the capillaries supplying these
structures [1].
Since 1965 several sets of criteria were proposed for clas-
sification of Sjo¨gren syndrome.Themost widely accepted are
the American-European Consensus Group (AECG) criteria
(from 1996, later revised in 2002), with no significant sensitiv-
ity and specificity difference to the criteria recently issued by
the American college of rheumatology (2012) [5]. Our patient
meets Sjo¨gren syndrome criteria according to AECG. SS-A
and SS-B antibodies were negative, but their low sensitivity
(40%) when nervous system is involved has been previously
reported [4].
There is scarce evidence in the literature about Sjo¨gren
syndrome treatment. Data regarding efficacy of corticoster-
oids and other immunosuppressive agents in extraglandular
involvement derive from studies designed for sicca symp-
toms. There is some evidence that Rituximab can be used as
a rescue therapy in refractory extraglandular features [6].
4. Conclusions
(i) Systemic autoimmune disturbances can affect both
central and peripheral nervous system and they can
present subacutely.
(ii) SS-A and SS-B antibodies are less sensitive in Sjo¨gren
syndrome when nervous system is involved.
(iii) When neurological features occur in Sjo¨gren syn-
drome they frequently precede sicca symptoms.
(iv) Before the clinical picture of a rapidly progressive
cognitive decline, a systemic and treatable cause must
be ruled out. Once infectious cause is excluded,
immunosuppression should be attempted, and a pos-
itive response should motivate an obstinate search for
a specific immunomediated disease [7].
Competing Interests
The authors declare that there is no conflict of interests
regarding the publication of this paper.
4 Case Reports in Neurological Medicine
References
[1] G. J. Tobo´n, J.-O. Pers, V. Devauchelle-Pensec, and P. Youinou,
“Neurological disorders in primary sjo¨gren’s syndrome,” Auto-
immune Diseases, vol. 2012, Article ID 645967, 11 pages, 2012.
[2] F. C. Soliotis, C. P. Mavragani, and H. M. Moutsopoulos, “Cen-
tral nervous system involvement in Sjo¨gren’s syndrome,”Annals
of the Rheumatic Diseases, vol. 63, no. 6, pp. 616–620, 2004.
[3] R. J. Caselli, B. F. Boeve, B. W. Scheithauer, J. D. O’Duffy, and G.
G. Hunder, “Nonvasculitic autoimmune inflammatory menin-
goencephalitis (NAIM): a reversible form of encephalopathy,”
Neurology, vol. 53, no. 7, pp. 1579–1581, 1999.
[4] S. Delalande, J. de Seze, A.-L. Fauchais et al., “Neurologic mani-
festations in primary Sjo¨gren syndrome: a study of 82 patients,”
Medicine, vol. 83, no. 5, pp. 280–291, 2004.
[5] A. Rasmussen, J. A. Ice, H. Li et al., “Comparison of the Ameri-
can-European Consensus Group Sjo¨gren’s syndrome classifica-
tion criteria to newly proposed American College of Rheuma-
tology criteria in a large, carefully characterised sicca cohort,”
Annals of the Rheumatic Diseases, vol. 73, no. 1, pp. 31–38, 2014.
[6] M. Ramos-Casals, R. Solans, J. Rosas et al., “Primary Sjo¨gren
syndrome in Spain: clinical and immunologic expression in 1010
patients,”Medicine, vol. 87, no. 4, pp. 210–219, 2008.
[7] G. S. Day and D. F. Tang-Wai, “When dementia progresses
quickly: a practical approach to the diagnosis and management
of rapidly progressive dementia,” Neurodegenerative disease
management, vol. 4, no. 1, pp. 41–56, 2014.
